The New Challenge For The Architect Of Wegovy

Mads Krogsgaard Thomsen, CEO of the Novo Nordisk Foundation and the man who supervised the development of semaglutide, describes the unprecedented growth of the obesity market and what might come next for Novo.

Mads Thomsen
Mads Krogsgaard Thomsen • Source: Novo Nordisk Foundation

Few people are better placed to comment on the phenomenon that is Novo Nordisk A/S's stunning growth in the past couple years with Ozempic and Wegovy than Mads Krogsgaard Thomsen, the man who supervised the development of the diabetes and obesity blockbusters and is now the CEO of the foundation that controls the Danish drugmaker.

More from C-Suite Speaks

Rising Leaders 2025: Amir Hefni Puts Optimism Into Action At Resolution Therapeutics

 
• By 

In Vivo Rising Leader Amir Hefni, CEO of Resolution Therapeutics, discusses the company's advancements in macrophage cell therapies for inflammatory and fibrotic diseases, and his transition from big pharma to biotech leadership.

How Charl Van Zyl Is Reimagining Lundbeck

 
• By 

Lundbeck CEO Charl van Zyl spoke with In Vivo about the Danish company’s multipronged transformation, one that involves a rethink of company culture, pipeline strategy and a sharpened focus on innovation in rare neurological disorders.

Antag Therapeutics: Developing Peptide-Based Treatments For Obesity Management

 
• By 

Antag CEO Joerg Moeller talked to In Vivo about the young company’s gilded roots, and how its GIP receptor antagonist asset will differentiate in the crowded obesity market.

Regenxbio’s Triple Threat: Partnered Programs, DMD Progress And In-House Manufacturing

 
• By 

Regenxbio is riding a wave these days, with all three of its clinical-stage programs set to reach critical milestones this year and recent positive news on its DMD gene therapy, just as Sarepta suffered a setback with a death related to its DMD treatment. In Vivo spoke with CEO Curran Simpson about the company’s plans and strategic decisions.

More from Leadership

How Charl Van Zyl Is Reimagining Lundbeck

 
• By 

Lundbeck CEO Charl van Zyl spoke with In Vivo about the Danish company’s multipronged transformation, one that involves a rethink of company culture, pipeline strategy and a sharpened focus on innovation in rare neurological disorders.

Antag Therapeutics: Developing Peptide-Based Treatments For Obesity Management

 
• By 

Antag CEO Joerg Moeller talked to In Vivo about the young company’s gilded roots, and how its GIP receptor antagonist asset will differentiate in the crowded obesity market.

Cracking Through ‘The Bamboo Ceiling’: East Asians Reach For Pharma Leadership

 
• By 

Despite the significant presence of East Asian professionals in the pharmaceutical industry, their representation in top leadership roles remains disproportionately low. This disparity can be attributed to cultural bias, limited access to influential networks, and systemic barriers within corporate structures.